Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …

BACKGROUND Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor,
with a high risk of recurrence and malignant transformation into high-grade gliomas. Given …

Recent successes in cancer immunotherapy have been tempered by sub-optimal clinical
responses in the majority of patients. The impaired anti-tumor immune responses observed …

Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many
different tumor types. Superior overall survival over chemotherapy has been reported in …

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has
a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or …

To date, a lot of nanotechnological optitions are available for targeted drug delivery.
Extracellular vesicles (EVs) are membrane structures that cells use for storage, transport …

In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy:(i) …

Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in
adults. As supplements to standard of care (SOC), various immunotherapies improve the …